Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence Part B Step Therapy Prior Auth Policy |…
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy N/A

    Medicare Part B Step Therapy Criteria for Part B Drugs

    Customize your policy alerts

    Sign up for all Providence Health Plan policy alerts

    Know when Providence Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy protocols, prior authorization expectations, and the list of Part B medications (by HCPCS/J-codes and others) subject to step requirements for Providence Medicare Advantage members.

    Policy Summary
    PayerProvidence Health Plan
    PolicyMedicare Part B Step Therapy Criteria for Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionPrescribers must obtain prior authorization for Step 2 and Step 3 drugs and document why prior steps failed, are contraindicated, or provide evidence of prior use within 365 days.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    365 dayslook-back period exempting members who received the non-preferred drug

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Step 1–3
    step levels used to classify drugs
    MultipleHCPCS procedure codes listed for Part B drugs
    Phone & TTYmember service contact

    Coverage Criteria

    Step therapy sequence and authorization

    Covered when following step therapy rules are satisfied

    Step therapy sequence: Member must trial Step 1 (preferred) drug before Step 2; must trial Step 1 and Step 2 before Step 3 when applicable.N/A

    Step 1 drugs usually require prior authorization; Step 2 and Step 3 always require prior authorization. For Step 2 and Step 3 the prescriber must document why prior steps failed or are contraindicated, or provide evidence of prior administration within the past 365 days.

    Recent use exemption

    Recent use exemption: If member received the non-preferred drug within the past 365 days, the step therapy requirement does not apply.365 days

    Evidence of administration within 365 days should be provided.

    The step therapy requirement does not apply to members who have already received the non-preferred drug within the past 365 days. Evidence of administration within this 365-day look-back should be provided to support exemption from the step sequence.

    Coding and Procedure Codes

    Part B HCPCS/J-codes (selection)HCPCS
    J3262Actemra (Tocilizumab)
    J0791Adakveo (Crizanlizumab-tmca)
    J7173Alhemo (Concizumab-mtci)
    J1552Alyglo (Immune globulin, gamma)
    Q5126Alymsys (Bevacizumab-maly)
    J1554Asceniv (Immune globulin)
    J9035Avastin (Bevacizumab)
    J3145Aveed (Testosterone undecanoate)
    Q5121Avsola (Infliximab-axxq)
    Q5156Avtozma (Tocilizumab-anoh)
    1–10 of 13
    1/2
    Additional Part B codes (continued list)HCPCS
    Q5152Bkemv (Eculizumab-aeeb)
    Q5158Bomyntra/Conexxence (Denosumab-bnht)
    J9054Boruzu (Bortezomib)
    J2329Briumvi (Ublituximab)
    J3392Casgevy (Exagemglogene autotemcel)
    J3490Miscellaneous HCPCS (multiple drugs listed)
    J0717Cimzia IV (Certolizumab)
    J2786Cinqair (Reslizumab)
    J0598Cinryze (C1 esterase inhibitor)
    J3247Cosentyx IV (Secukinumab)
    1–10 of 20
    1/2
    Further Part B HCPCS/J-codesHCPCS
    J1299Soliris (Eculizumab)
    J2350Ocrevus (Ocrelizumab)
    J0889Jesduvroq (Daprodustat)
    J0888Mircera (Epoetin beta) non-ESRD use
    J0219Nexviazyme (Avalglucosidase alfa)
    J2802Nplate (Romiplostim)
    J2182Nucala (Mepolizumab)
    Q5122Nyvepria (Pegfilgrastim-apgf)
    J9312Rituxan (Rituximab)
    Q5119Ruxience (Rituximab-pvvr)
    1–10 of 20
    1/2
    End of listed codesHCPCS
    J9334Vyvgart Hytrulo (Efgartigimod alfa/hyaluronidase)
    Q5138Wezlana (Ustekinumab-auub)
    J3490/C9399Winrevair (Sotatercept-csrk) / miscellaneous codes
    J1558Xembify (Immune globulin)
    J2357Xolair (Omalizumab)
    Q5100Yesintek (Ustekinumab-kfce)
    J1553Yimmugo (Immune globulin (IgG)-dira human)
    Q5120Ziextenzo (Pegfilgrastim-bmez)
    inv-08: Prior use look-back — member received the non-preferred drug within the past 365 days
    Look-back period365 days — if member received the non-preferred drug within the past 365 days, the step therapy requirement does not apply.
    Evidence requiredDocumentation of administration within the past 365 days must be provided by the prescriber to support the exemption.
    Applies toNon-preferred (Step 2 or Step 3) drugs listed in the Part B step therapy criteria.
    Effect on prior authorizationExemption from step therapy does not necessarily waive any prior authorization or quantity limits that may still apply to the drug.

    Provider Actions & Authorization

    Prior Authorization

    Prior authorization required for Step 2/3 (Step 1 usually)

    Step 2 and Step 3 drugs always require prior authorization; Step 1 drugs usually require prior authorization unless the drug-specific list indicates otherwise.

    • Provider must submit a prior authorization request for any Step 2 or Step 3 agent.
    • If a Step 1 drug requires prior authorization, the list will note that — follow the drug-specific instruction.
    Step Therapy

    Follow the step therapy sequence

    Prescribers must follow the step therapy sequence: a trial of a preferred (Step 1) drug is required before coverage of a Step 2 agent, and a trial of Step 1 and Step 2 drugs is required before a Step 3 agent.

    • Step 2 always follows Step 1; Step 3 requires prior trial of both Step 1 and Step 2.
    • Confirm member eligibility and applicable step levels on the drug-specific list before requesting coverage.

    Background

    Medicare Part B covers many physician‑administered and infusion drugs and biologics that may be subject to step therapy to promote the use of preferred therapies first. Step therapy requires a trial of a preferred (Step 1) drug before covering a non‑preferred (Step 2 or Step 3) drug. Both preferred and non‑preferred drugs may still require prior authorization or quantity limits. Step therapy protocols in this document may coordinate treatment expectations across Part B and Part D when clinically appropriate.

    Definitions

    inv-14: Step therapy — A coverage rule requiring trial of a preferred drug (Step 1) before paying for a non-preferred agent (Step 2 or 3). Exemptions apply if t...
    DefinitionStep therapy is a coverage rule requiring trial of a preferred drug (Step 1) before paying for a non-preferred agent (Step 2 or Step 3).
    Step sequenceStep 1 (preferred) must be tried before Step 2; Step 1 and Step 2 must be tried before Step 3 when applicable.
    Prior authorization — most actionableStep 2 and Step 3 drugs always require prior authorization; Step 1 drugs usually require prior authorization unless the drug-specific list indicates otherwise.
    Documentation for nonpreferred stepsFor Step 2 or Step 3, prescriber must document why prior steps failed or are contraindicated, or show evidence of prior administration within specified look-back periods.
    ExemptionStep therapy does not apply if the member received the non-preferred drug within the prior 365 days.

    Initial Therapy Criteria

    Initial therapy and Step 1 expectations

    General initial therapy expectations for step therapy

    Initial step: Prescriber should initiate preferred (Step 1) therapy where clinically appropriate; prior authorization is usually required for Step 1 agents unless the drug-specific list indicates otherwise.N/A

    Step 2 and Step 3 always require prior authorization and require documentation that Step 1 (and Step 2 when required) were ineffective or contraindicated, or evidence of prior administration within 365 days.

    Step Therapy Details

    StepRequirementPrior authorizationProvider documentation needed
    Step 1 (Preferred)
    Member should be initiated on a preferred (Step 1) agent before progressing to Step 2.
    Usually required unless the drug-specific list indicates otherwise.
    If prior authorization is required, prescriber must submit clinical rationale for use; if the Step 1 drug does not require prior authorization this will be noted in the drug list.
    Policy Summary
    PayerProvidence Health Plan
    PolicyMedicare Part B Step Therapy Criteria for Part B Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionPrescribers must obtain prior authorization for Step 2 and Step 3 drugs and document why prior steps failed, are contraindicated, or provide evidence of prior use within 365 days.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Procedure CodesProvider Actions & AuthorizationBackgroundDefinitionsInitial Therapy CriteriaStep Therapy Details
    Documentation Required

    Document prior therapy failure, contraindication, or prior use

    For Step 2 and Step 3 drugs, the prescriber must document one of the acceptable reasons for bypassing prior steps or provide evidence of prior use within the look-back period.

    • Document why the Step 1 (for Step 2) or Step 1 and Step 2 (for Step 3) drugs were ineffective or not tolerated, or why they are contraindicated.
    • Alternatively, provide clinical details showing the member received the required prior step drug(s) within the past 365 days.
    Denial Risk

    Risk of non-coverage if prior authorization is not provided

    Failure to obtain and submit required prior authorization documentation for Step 1 (when required), Step 2, or Step 3 drugs may result in denial of coverage.

    • Submit complete prior authorization with the required clinical justification or evidence of prior administration within 365 days to avoid non-coverage.
    • Check the drug-specific list for any Step 1 exceptions and for the required supporting details for Step 2/3 requests.